Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Renal transplant patient's aged between 18 and 60 years old.~2. Heart rate in radial pulse and seated between 50 and 100 bpm.~3. Systolic blood pressure between 100 and 140 and diastolic between 50 to 90.~4. Absence of any clinical physical, psychological or psychiatric condition that would prevent from the protocol described follow-up.~5. Estimated glomerular filtration rate greater than 40 ml / min.~6. Proteinuria \< 0.5 g / d.~7. Renal transplantation at least 6 months ago.~8. Immunosuppressant based on calcineurin inhibitors.~9. Hemoglobin \> 11 g / dl.~10. Body mass index (BMI) \< 35 kg/m2.~11. Indication for conversion to everolimus and granting of written informed consent.~Exclusion Criteria:~1. Diabetes mellitus~2. Treatment with erythropoiesis stimulating drugs~3. Treatment with β blockers drugs~4. Participation in any clinical trial in the last 30 days prior to the inclusion.~5. Any other physical illness, psychological or psychiatric condition that could difficult the follow-up of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)

Based on this trial design, predict the completion outcome and termination type (if applicable).